Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trospium chloride/xanomeline - Karuna Therapeutics

Next Previous
Search
Drug Profile

Trospium chloride/xanomeline - Karuna Therapeutics

Alternative Names: BMS-986510; COBENFY; Karuna-Xanomeline-Trospium - Karuna Therapeutics; KarXT - Karuna Therapeutics; Trospium chloride/LY-246708 - Karuna Therapeutics; Trospium chloride/xanomeline tartrate - Karuna Therapeutics; Xanomeline tartrate/ trospium chloride - Karuna Therapeutics; Xanomeline/trospium chloride - Karuna Therapeutics

Latest Information Update: 07 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PureTech Health
  • Developer Karuna Therapeutics; ZAI Lab
  • Class Analgesics; Antidementias; Antipsychotics; Antispasmodics; Benzhydryl compounds; Benzilates; Esters; Nortropanes; Pyridines; Small molecules; Spiro compounds; Thiadiazoles; Urologics
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Schizophrenia
  • Phase III Psychotic disorders
  • Discontinued Pain

Most Recent Events

  • 30 Apr 2025 Bristol-Myers Squibb plans the phase III BALSAM-2 trial for Bipolar Disorder in Croatia, India, Israel, Italy, Romania, Slovakia, Spain, Sweden and the US in June 2025 (NCT06951711)
  • 30 Apr 2025 Bristol-Myers Squibb plans the phase III BALSAM-1 trial for Bipolar disorder in Argentina, Australia, Bulgaria, Hungary, Japan, New Zealand, Poland, the US, in June 2025 (NCT06951698)
  • 27 Apr 2025 Bristol-Myers Squibb plans the phase III ADEPT-5 trial for Psychotic disorders (Combination therapy) (PO), in July 2025 , (NCT06947941)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top